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Objective: To assess the change in the Intermittent and Constant Osteoarthritis Pain (ICOAP)-scale scores
in patients taking duloxetine or placebo and to characterize the responsiveness of the ICOAP by
comparing the effect size associated with its scales to effect sizes seen with other pain scales used in this
study.
Methods: This was a secondary analysis of data from a 10-week, double-blind, randomized, ﬂexible-dose,
placebo-controlled trial that enrolled patients who had persistent moderate pain due to osteoarthritis
(OA) of the knee, despite having received nonsteroidal anti-inﬂammatory drug (NSAID) therapy. The pain
measures used in this study (focusing on the drug-placebo difference at week 8) were patient-rated pain
severity, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), the Brief Pain
Inventory (BPI), and the ICOAP.
Results: The mean difference between duloxetine and placebo at week 8 for patient-rated pain severity,
the BPI average pain, WOMAC pain, and each ICOAP scale was statistically signiﬁcant (P < 0.001 for each).
The ICOAP total showed a moderate effect size of 0.53, whereas the constant and intermittent scores
showed effect sizes of 0.47 and 0.49, respectively. The patient-rated pain severity and the BPI average
pain showed similar moderate effect sizes of 0.59 and 0.53, respectively.
Conclusion: The study demonstrated efﬁcacy of duloxetine compared with placebo when using the ICOAP
scale in a placebo-controlled trial. The observed treatment effect size for the ICOAP scores was similar to
that for other reliable, valid and responsive pain assessments.
Clinical trials registration: ClinicalTrial.gov Identiﬁer: NCT01018680
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Pain is the most commonly reported symptom in patients with
osteoarthritis (OA) of the knee1. This pain may initially be associ-
ated with activity; however, as the disease progresses, it may
become more constant and is eventually associated with inter-
mittent episodes of greater pain. With the endorsement by the
Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMER-
ACT) and the Osteoarthritis Research Society International (OARSI),
the Intermittent and Constant Osteoarthritis Pain (ICOAP)2,3 ques-
tionnaire was recently developed as a pain assessment tool for knee
or hip OA. Various studies describe the utility of the ICOAPo: R. C. Risser, Eli Lilly and
5, USA. Tel: 1-317-433-4918.
sser).
s Research Society International. Pincluding how to evaluate the measurement properties and
examine the pain experience of patients with OA2,3. Additional
studies have reported the responsiveness of the ICOAP following
knee and hip replacement4, after 4 weeks of physical therapy for
knee OA5, and after 6 months in a randomized, double-blind
(nonplacebo-controlled) trial of various nonsteroidal anti-
inﬂammatory drug (NSAID) therapies in patients with knee or hip
OA6. Recently, Frakes et al.7 showed that duloxetine was superior to
placebo when added to NSAID therapy in the treatment of OA knee
pain over 8 weeks. The purpose of the present work is two-fold.
First, we provide results concerning the change in ICOAP-
measured pain in patients taking duloxetine or placebo. Second,
as this is the ﬁrst known placebo-controlled study to include the
ICOAP, we further characterize the responsiveness of the ICOAP by
comparing the effect size associated with its scales to the effect size
seen with other pain scales implemented in the study.ublished by Elsevier Ltd. All rights reserved.
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Methods
Study population
In this double-blind, randomized, placebo-controlled, 10-week,
ﬂexible-dose study of male and female patients greater than 40
years of age who met American College of Rheumatology (ACR)
clinical and radiographic criteria for OA of the knee8, patients were
required to have knee pain for 14 days/month in the 3 months
preceding study entry and report use of NSAIDs for treatment of
kneepainonmostdaysduring that period. Theenrolledpatientshad
persistent moderate pain (4 on a 0-to-10 numerical rating scale)
due to OA of the knee, despite having received optimized NSAID
therapy (speciﬁc drug, dose, and frequencyat investigator discretion
to reﬂect patient-physician decisions around efﬁcacy, tolerability,
and cost). Additional patient inclusion and exclusion criteria for this
study, as well as full study design details are provided in the previ-
ously published article associated with this clinical trial7. The study
protocol was approved by appropriate institutional review boards
(IRBs), and informed consentwas obtained from all patients prior to
study entry in accordance with the Declaration of Helsinki.
Study design
During the 2-week screening phase of the study, investigators
were asked to optimize the patient’s current NSAID treatment to
reﬂect patient-physician decisions around efﬁcacy, tolerability, and
cost. Patients who had at least a 70% compliance rate with the
telephone-based diary system and who had an average weekly pain
severity rating of 4 during the previous week were randomly allo-
cated to receive either 10weeksof duloxetine (Cymbalta, Eli Lillyand
Company) treatment or placebo added to the optimized NSAID ther-
apy. Patients allocated toduloxetineweregiven30mg/day for 1week,
followed by 60 mg/day for 2 weeks. At week 3 of active treatment,
patientswhohadameanaveragepain severity ratingof4during the
previous week had a blinded dose escalation to 120 mg/day. Week 8
was considered to be the efﬁcacy end point of this 10-week study.
Measurements
Patient-rated pain severity was the primary measure of efﬁcacy
in this study. Patients used a telephone-based diary system to re-
cord daily average pain severity considering the previous 24 h.
Daily pain ratings were based on a scale ranging from 0 (no pain) to
10 (pain as severe as you can imagine). For analysis, the daily rat-
ings were composed into weekly means, and focussed on the drug-
placebo difference at week 8 as the primary endpoint.
In addition, three measures of OA pain were obtained at each
treatment visit: the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC)9, the Brief Pain Inventory (BPI)10,
and the ICOAP2,3.
The WOMAC is designed to assess pain, stiffness, and physical
function in patients with OA of the knee or hip. It consists of 24
questions: ﬁve on pain, two on stiffness, and 17 on physical function,
each answered by using a 5-point scale ranging from 0 (none) to 4
(extreme). EachWOMACmulti-itemsubscale is normalized to values
between 0 (best condition) and 100 (worst condition). In these an-
alyses, the focus for the WOMAC is on the outcome assessing pain.
The BPI is a self-reported scale thatmeasures the severity of pain and
the interference of pain on function. Severity of pain was assessed
with fourquestions:patients assignscores to characterize theirworst
pain, least pain, average pain in the previous 24 h, and their current
pain. Pain ratings range from0 (no pain) to 10 (pain as bad as you can
imagine). Use of the ICOAP in this studywas based on an exploratory
objective. The ICOAP consists of 11 items each rated on a 5-point
(0¼ not at all/no pain, 1¼mildly, 2 ¼moderately, 3 ¼ severely, and4¼ extremely) anchored scale and assessed within the past week. A
score is produced for the constant pain subscale (0-20), intermittent
pain subscale (0-24), and total pain (0-44, calculated by summing the
subscale scores). Each score is normalized to values between 0 (best
condition) and 100 (worst condition). For both, the constant knee
pain, and the knee pain that comes and goes [intermittent], the pa-
tient is asked to select a response that best describes how intense the
pain has been during the pastweek, howmuch the pain affects sleep
and overall quality of life, and how frustrated or annoyed, and, upset
orworried the patient has been, due to the knee pain. In addition, the
patient is also asked how frequently the intermittent knee pain
occurred (0 ¼ never/no knee pain that comes and goes, 1 ¼ rarely,
2 ¼ sometimes, 3 ¼ often, and 4 ¼ very often).
Statistical analyses
The analyses were done on the intent-to-treat efﬁcacy popu-
lation. Only patients with a baseline and at least one postbaseline
measure were included in the analysis of each measure. Change in
the patient-rated pain severity was analyzed using a mixed-model
repeated measures (MMRM) approach which contained terms for
treatment, week, site, baseline severity rating, and treatment-by-
week and baseline-severity-rating-by-week interaction terms as
ﬁxed effects, and patient as a random effect. A similarly con-
structed MMRM model was used to analyze change in the BPI
average pain score, the WOMAC pain subscale, and the ICOAP
total, intermittent, and constant pain scores with visit replacing
week for these measures taken at each visit. The week 8 com-
parison between the duloxetine and placebo group was used for
the primary, secondary, and exploratory efﬁcacy measures. Esti-
mated [least squares (LS)] means by treatment at each week/visit
were compared using Student’s t-tests. The observed effect size
was derived as the difference in estimated means at week 8
divided by the estimated within-patient standard deviation (SD) at
week 8 as derived from the MMRM-based within-patient
variance-covariance matrix. Conﬁdence intervals (CIs) on the
observed effect size associated with treatment differences for
various measures of pain or function were computed using the
properties of the noncentral t-distribution and the interval
inversion principles described by Steiger and Fouladi11.
Statistical tests were performed at the two-tailed 0.05 level of
signiﬁcance and 95% CIs were computed. All analyses were per-
formed with SAS software version 9.1 (Cary, NC, USA).
Results
A total of 524 patients were randomly assigned to treatment,
264 to duloxetine and 260 to placebo7. The average age of the pa-
tients was 61 years (age range: 40e92 years), 80.9% of patients
were white, and 57.1% were women. Ibuprofen (45.6%) and nap-
roxen (34.2%) were the most frequently used NSAIDs by patients
overall, while meloxicam, celecoxib, and diclofenac accounted for a
majority of the remaining NSAIDs that were used.
The mean changes and effect sizes for the ICOAP results are
presented in Table I. The results for the other measures, while
previously reported7, are included here for comparison purposes.
The mean difference between duloxetine and placebo at week 8 for
the patient-rated pain severity, the BPI average pain score, WOMAC
pain subscale, and ICOAP subscales was statistically signiﬁcant
(P < 0.001 for each) (Table I). Further, the ICOAP total pain score
showed a moderate effect size12 of 0.53, whereas the constant and
intermittent scores showed effect sizes of 0.47 and 0.49, respec-
tively (Table I). The patient-rated pain severity and the BPI average
pain score showed similar moderate effect sizes of 0.59 and 0.53,
respectively. The WOMAC pain subscale had the lowest effect size
(0.43) of the pain measures used in the study (Table I).
Table I
Effect size estimates e efﬁcacy measures
Variable LS mean estimate* at week 8 LS mean difference Common SD Effect size 95% CI for effect size estimate
Duloxetine Placebo
Patient-rated pain severity 2.46 1.55 0.91*** 1.53 0.59 (0.41, 0.78)
Brief Pain Inventory average pain score 2.56 1.54 1.02*** 1.93 0.53 (0.34, 0.71)
WOMAC pain subscale score 4.41 3.12 1.28*** 3.00 0.43 (0.24, 0.61)
ICOAP total pain score 9.97 6.53 3.44*** 6.50 0.53 (0.34, 0.71)
ICOAP constant pain score 4.54 2.95 1.59*** 3.39 0.47 (0.28, 0.65)
ICOAP intermittent pain score 5.44 3.58 1.86*** 3.80 0.49 (0.30, 0.68)
***P < 0.001 based on a Student’s t-test comparing improvement between duloxetine and placebo at week 8 from estimates derived using mixed-model repeated measures.
* Change from baseline to end point using the mixed-model repeated measures approach.
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the efﬁcacy of duloxetine compared with placebo in the treatment
of OA knee pain.
Discussion
Duloxetine added to NSAID therapy provided signiﬁcant pain
reduction, based on the primary measure of the patient-rated pain
severity, as well as for various secondary and exploratory pain
ratings including the BPI average pain score, the WOMAC pain
subscale, and the ICOAP constant pain subscale, intermittent pain
subscale, and total pain scale, which further supports the efﬁcacy of
duloxetine treatment for patients with OA knee pain. The effect size
estimates for the ICOAP are very similar to the effect size estimates
of the other pain scales used in this study, thereby suggesting that
the ICOAP could be used as a potential primary efﬁcacy measure in
trials of interventions for OA pain.
The results of these analyses extend published information
about the development, validation, and responsiveness of the
ICOAP2,3,4,5,6. Speciﬁcally, this is the ﬁrst report to demonstrate
similar or greater effect sizes for the ICOAP for an active comparator
vs placebo in patients with OA knee pain. The effect size for the
ICOAP total score was of similar magnitude to the effect sizes seen
with well-validated measures such as the BPI, the patient-rated
pain severity, and to some extent the WOMAC.
It is possible that compared to the ICOAP (particularly for the
total score), the WOMAC may be a less robust measure of pain
improvement in studies of interventions that are not directed
speciﬁcally to function; the evaluation of OA pain using the
WOMAC is heavily inﬂuenced by the effects of function on pain
with this scale2,13, as patients are asked to report on pain experi-
enced with activities such as walking, standing, and climbing stairs.
This study demonstrated efﬁcacy of duloxetine when compared
with placebo using the ICOAP scale in a placebo-controlled trial. In
addition, the observed treatment effect size for the ICOAP scales
compared well with effect size estimates for other pain assess-
ments. Considering previous work showing the reliability, validity,
and sensitivity to change for the ICOAP2,3,4,6, our last ﬁnding sug-
gests that the ICOAP might be considered as a primary measure for
use in future placebo-controlled trials of OA.
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